Vaccine injury compensation
Executive Summary
House Government Reform/Criminal Justice, Drug Policy & Human Resources Subcommittee will hold a hearing Sept. 17 to discuss the Vaccine Injury Compensation Program. Invited witnesses include VICP Director Thomas Balbier, an un-named medical expert on vaccine injuries, a lawyer involved in vaccine injury litigation and families of those allegedly harmed. At an Aug. 3 hearing of the full committee, Subcommittee Chairman Mica (R-Fla.) requested that Surgeon General David Satcher, MD/PhD, submit recommendations to his staff on potential legislation to allocate VICP funds for vaccine safety research (1"The Pink Sheet" Aug. 9, p. 14)
You may also be interested in...
Vaccine Comp Surplus Should Go To Increased Safety Research, HHS Says
HHS would like to use a portion of the $1.4 bil. Vaccine Injury Compensation Program to fund studies of vaccine safety and adverse events.
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials